{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:23:38Z","timestamp":1770459818049,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgkin B-cell lymphoma receiving the first R-CHOP cycle.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a subanalysis of the retrospective observational study STOP FN in NHL 2 (UMIN000029534). Patient characteristics, changes in neutrophil count, incidence and severity of neutropenia, and risk factors for dose reduction\/delay of R-CHOP were assessed by G-CSF formulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 234 patients in cycle 1, 25.6% received no G-CSF preparation, 52.1% received daily G-CSF, and 22.2% received pegfilgrastim. Pegfilgrastim use was most frequent among patients aged \u2265\u00a080\u2009years, while that of daily G-CSF was most frequent in patients with lymphocyte count (LC) &lt;\u20091000 cells\/\u03bcL. Changes in neutrophil count were more marked with pegfilgrastim compared with daily G-CSF and no G-CSF. Relevant factors for G-CSF preparation selection in the first R-CHOP cycle were age\u2009\u2265\u200980\u2009years and LC &lt;\u20091000 cells\/\u03bcL; for chemotherapy dose reduction were FN onset in cycle 1 and female sex; and for dose delay was hemoglobin (&lt;\u200912\u2009g\/dL). After cycle 2 and onward, pegfilgrastim use increased markedly (72.6%) compared with cycle 1 (22.2%), with significantly greater proportions continuing pegfilgrastim use and switching from daily G-CSF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Relevant factors for G-CSF preparation selection were age\u2009\u2265\u200980\u2009years and LC &lt;\u20091000 cells\/\u03bcL. The use of pegfilgrastim increased markedly after cycle 2. These results may be useful for selecting appropriate G-CSF preparations in the first R-CHOP cycle.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>UMIN000029534; registered on 13 October 2017, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000033733\">https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000033733<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08068-0","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T19:03:01Z","timestamp":1617735781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions\/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)"],"prefix":"10.1186","volume":"21","author":[{"given":"Masahiro","family":"Yokoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihito","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Nukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"8068_CR1","doi-asserted-by":"publisher","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):111\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw325.","DOI":"10.1093\/annonc\/mdw325"},{"key":"8068_CR2","doi-asserted-by":"publisher","unstructured":"Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Cancer Netw. 2008;6(2):109\u201318. https:\/\/doi.org\/10.6004\/jnccn.2008.0012.","DOI":"10.6004\/jnccn.2008.0012"},{"key":"8068_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","volume":"120","author":"Y Lalami","year":"2017","unstructured":"Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol. 2017;120:163\u201379. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.11.005.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"8068_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","volume":"77","author":"H Wildiers","year":"2011","unstructured":"Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol. 2011;77(3):221\u201340. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.02.002.","journal-title":"Crit Rev Oncol Hematol."},{"key":"8068_CR5","doi-asserted-by":"publisher","unstructured":"Terada Y, Nakamae H, Aimoto R, Kanashima H, Sakamoto E, Aimoto M, et al. Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res. 2009;28(1):116. https:\/\/doi.org\/10.1186\/1756-9966-28-116.","DOI":"10.1186\/1756-9966-28-116"},{"issue":"10","key":"8068_CR6","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258\u201366. https:\/\/doi.org\/10.1002\/cncr.21847.","journal-title":"Cancer."},{"key":"8068_CR7","doi-asserted-by":"publisher","unstructured":"Yokoyama M, Kusano Y, Takahashi A, Inoue N, Ueda K, Nishimura N, et al. Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan. Support Care Cancer. 2017;25(11):3313\u201320. https:\/\/doi.org\/10.1007\/s00520-017-3747-z.","DOI":"10.1007\/s00520-017-3747-z"},{"issue":"2","key":"8068_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3109\/10428194.2015.1045894","volume":"57","author":"GH Lyman","year":"2016","unstructured":"Lyman GH, Crawford J, Tomita D, Whittaker S, Dale DC. Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2016;57(2):283\u201390. https:\/\/doi.org\/10.3109\/10428194.2015.1045894.","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"8068_CR9","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158\u201367. https:\/\/doi.org\/10.1200\/JCO.2006.08.8823.","journal-title":"J Clin Oncol"},{"key":"8068_CR10","doi-asserted-by":"publisher","unstructured":"Yokoyama M, Kusano Y, Nishihara A, Inoue N, Nishimura N, Mishima Y, et al. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2). Support Care Cancer. 2019;28(2):571\u20139. https:\/\/doi.org\/10.1007\/s00520-019-04802-4.","DOI":"10.1007\/s00520-019-04802-4"},{"key":"8068_CR11","volume-title":"Practical guideline of febrile neutropenia (FN) Clinical practice guidelines in Japan","author":"Japanese Society of Oncology","year":"2012","unstructured":"Japanese Society of Oncology. Practical guideline of febrile neutropenia (FN) Clinical practice guidelines in Japan. Tokyo: Japanese Society of Oncology; 2012. http:\/\/minds4.jcqhc.or.jp\/minds\/febrile-neutropenia\/febrile-neutropenia-front-matter.pdf. Accessed 13 Apr 2020"},{"issue":"4","key":"8068_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.6004\/jnccn.2005.0031","volume":"3","author":"GH Lyman","year":"2005","unstructured":"Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Cancer Netw. 2005;3(4):557\u201371. https:\/\/doi.org\/10.6004\/jnccn.2005.0031.","journal-title":"J Natl Compr Cancer Netw"},{"key":"8068_CR13","doi-asserted-by":"publisher","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199\u2013212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488.","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"8068_CR14","doi-asserted-by":"publisher","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013.","DOI":"10.1016\/j.ejca.2010.10.013"},{"key":"8068_CR15","volume-title":"Clinical practice guidelines. Recommendations for the use of G-CSF","author":"Japan Society of Clinical Oncology","year":"2013","unstructured":"Japan Society of Clinical Oncology. Clinical practice guidelines. Recommendations for the use of G-CSF. (2013). http:\/\/www.jsco-cpg.jp\/item\/30\/index.html. Accessed 13 Apr 2020."},{"key":"8068_CR16","first-page":"687","volume":"41","author":"K Kiura","year":"2014","unstructured":"Kiura K. Overview of guidelines for proper use of the G-CSF (2013 edition). Gan To Kagaku Ryoho. 2014;41:687\u201390 [Article in Japanese].","journal-title":"Gan To Kagaku Ryoho"},{"issue":"18","key":"8068_CR17","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"OA Clark","year":"2005","unstructured":"Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198\u2013214. https:\/\/doi.org\/10.1200\/JCO.2005.05.645.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8068_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11(1):404. https:\/\/doi.org\/10.1186\/1471-2407-11-404.","journal-title":"BMC Cancer"},{"issue":"2","key":"8068_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10549-018-4837-4","volume":"171","author":"AL Kong","year":"2018","unstructured":"Kong AL, Nattinger AB, McGinley E, Pezzin LE. The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer. Breast Cancer Res Treat. 2018;171(2):477\u201388. https:\/\/doi.org\/10.1007\/s10549-018-4837-4.","journal-title":"Breast Cancer Res Treat"},{"key":"8068_CR20","doi-asserted-by":"publisher","unstructured":"Hilton J, Vandermeer L, Sienkiewicz M, Mazzarello S, Hutton B, Stober C, et al. Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients. Support Care Cancer. 2018;26(7):2323\u201331. https:\/\/doi.org\/10.1007\/s00520-018-4074-8.","DOI":"10.1007\/s00520-018-4074-8"},{"issue":"12","key":"8068_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12032-016-0850-9","volume":"33","author":"U Vitolo","year":"2016","unstructured":"Vitolo U, Angrili F, DeCosta L, Wetten S, Federico M. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin\u2019s lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy. Med Oncol. 2016;33(12):139. https:\/\/doi.org\/10.1007\/s12032-016-0850-9.","journal-title":"Med Oncol"},{"key":"8068_CR22","doi-asserted-by":"publisher","unstructured":"Lin WT, Wen YW, Chien CR, Gau CS, Chiang SC, Hsiao FY. Suboptimal duration of granulocyte colony-stimulating factor use and chemotherapy-induced neutropenia in women diagnosed with breast cancer. Clin Ther. 2014;36(9):1287\u201394. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.034.","DOI":"10.1016\/j.clinthera.2014.06.034"},{"key":"8068_CR23","doi-asserted-by":"publisher","unstructured":"Lugtenburg P, Silvestre AS, Rossi FG, Noens L, Krall W, Bendall K, et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin Lymphoma Myeloma Leuk. 2012;12(5):297\u2013305. https:\/\/doi.org\/10.1016\/j.clml.2012.06.004.","DOI":"10.1016\/j.clml.2012.06.004"},{"key":"8068_CR24","doi-asserted-by":"publisher","unstructured":"Choi CW, Sung HJ, Park KH, Yoon SY, Kim SJ, Oh SC, et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol. 2003;73(4):263\u20136. https:\/\/doi.org\/10.1002\/ajh.10363.","DOI":"10.1002\/ajh.10363"},{"key":"8068_CR25","doi-asserted-by":"publisher","unstructured":"Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, et al. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer. Support Care Cancer. 2014;22(12):3219\u201326. https:\/\/doi.org\/10.1007\/s00520-014-2328-7.","DOI":"10.1007\/s00520-014-2328-7"},{"key":"8068_CR26","doi-asserted-by":"publisher","unstructured":"Park S, Han B, Cho JW, Woo SY, Kim S, Kim SJ, et al. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer. 2014;66(2):225\u201333. https:\/\/doi.org\/10.1080\/01635581.2014.867065.","DOI":"10.1080\/01635581.2014.867065"},{"issue":"7","key":"8068_CR27","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00520-011-1241-6","volume":"20","author":"A Chan","year":"2012","unstructured":"Chan A, Chen C, Chiang J, Tan SH, Ng R. Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer. 2012;20(7):1525\u201332. https:\/\/doi.org\/10.1007\/s00520-011-1241-6.","journal-title":"Support Care Cancer"},{"key":"8068_CR28","doi-asserted-by":"publisher","unstructured":"M\u0105dry R, Pop\u0142awska L, Haslbauer F, \u0160afanda M, Ghizdavescu D, Benkovicova J, et al. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. Wien Klin Wochenschr. 2016;128(7-8):238\u201347. https:\/\/doi.org\/10.1007\/s00508-015-0917-1.","DOI":"10.1007\/s00508-015-0917-1"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08068-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-08068-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08068-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T19:06:44Z","timestamp":1617736004000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08068-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8068"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08068-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]},"assertion":[{"value":"29 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional Ethical Review Board. The analysis was conducted in accordance with the Declaration of Helsinki and Ethical Guidelines for Medical Research on Individuals, the Law Concerning the Protection of Personal Information, and all other applicable laws and regulations concerning the handling of personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This was a retrospective observational study on data obtained from medical records. For this reason, the Ethical Review Board waived the need for obtaining informed consent from the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MY reports personal fees (for consultancy) from Chugai Pharmaceutical, outside the submitted work. NN reports personal fees (for consultancy) from Chugai Pharmaceutical, outside the submitted work. YM reports personal fees (for consultancy) from Chugai Pharmaceutical, outside the submitted work. TN reports personal fees (for employment) from Kyowa Kirin, during the conduct of the study. KH reports personal fees (for expert testimony) from Eisai and Otsuka Pharmaceutical, grants from AbbVie, Gilead Sciences, Celgene, Solasia Pharma, Pfizer, Bristol Myers Squibb, Janssen Pharmaceutical, Ono Pharmaceutical, and Chugai Pharmaceutical, personal fees (for speakers\u2019 bureau and others) from Takeda Pharmaceutical and Taiho Pharmaceutical, personal fees (for speakers\u2019 bureau) from Celgene, and personal fees (for others) from Kyowa Kirin, outside the submitted work. YT reports grants from Bristol Myers Squibb and personal fees (for speakers\u2019 bureau) from Chugai Pharmaceutical, Novartis, Janssen Pharmaceutical, Celgene, Ono Pharmaceutical, Takeda Pharmaceutical, and MSD. YK and NI have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"358"}}